Detection of sputum cofilin-1 as indicator of malignancy

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author RANGEL, M.P. FMUSP-HC
ANTONANGELO, L. FMUSP-HC
ACENCIO, M.M.P. FMUSP-HC
FARIA, C.S. FMUSP-HC
DE SÁ, V.K.
LEÃO, P.S.
FARHAT, C.
FABRO, A.T.
LONGATTO FILHO, A. FMUSP-HC
REIS, R.M.
TAKAGAKI, T. FMUSP-HC
CAPELOZZI, V.L. FMUSP-HC
dc.date.issued 2018
dc.identifier.citation BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, v.51, n.8, p.e7138, 2018
dc.identifier.issn 0100-879X
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/26785
dc.description.abstract Cofilin-1 (CFL1), a small protein of 18 kDa, has been studied as a biomarker due to its involvement in tumor cell migration and invasion. Our aim was to evaluate CFL1 as an indicator of malignancy and aggressiveness in sputum samples. CFL1 was analyzed by ELISA immunoassay in the sputum of 73 lung cancer patients, 13 cancer-free patients, and 6 healthy volunteers. Statistical analyses included ANOVA, ROC curves, Spearman correlation, and logistic regression. Sputum CFL1 levels were increased in cancer patients compared to cancer-free patients and volunteers (P<0.05). High expression of sputum CFL1 was correlated to T4 stage (P=0.01) and N stage (P=0.03), tobacco history (P=0.01), and squamous cell carcinoma histologic type (P=0.04). The accuracy of sputum CFL1 in discriminating cancer patients from cancer-free patients and healthy volunteers were 0.78 and 0.69, respectively. CFL1 at a cut-off value of 415.25 pg/mL showed sensitivity/specificity of 0.80/0.70 in differentiating between healthy volunteers and cancer patients. Sputum CFL1 was also able to identify cancer-free patients from patients with lung cancer. The AUC was 0.70 and, at a cut-off point ≥662.63 pg/mL, we obtained 60% sensitivity and 54% specificity. Logistic regression analysis controlled for tobacco history, histologic types, and N stage showed that cancer cell-associated CFL1 was an independent predictor of death. Smoker patients with squamous cell carcinoma, lymph node metastasis and sputum CFL1>1.475 pg/mL showed augmented chance of death, suggesting lung cancer aggressiveness. CFL1 presented diagnostic value in detecting lung cancer and was associated to tumor aggressiveness.
dc.description.sponsorship · Sao Paulo Research Foundation (FAPESP) [2010/11005-5]; National Council for Scientific and Technological Development (CNPq) [471939/2010-2, 483005/2012-6]
dc.language.iso eng
dc.publisher Associação Brasileira de Divulgação Científica
dc.relation.ispartof Brazilian Journal of Medical and Biological Research
dc.rights openAccess
dc.subject Lung cancer; Cofilin-1; Sputum; Liquid-biopsy; Metastases; Biomarker
dc.subject.other LUNG-CANCER; DEPOLYMERIZATION; METASTASIS; INVASION; DYNAMICS; CELLS
dc.title Detection of sputum cofilin-1 as indicator of malignancy
dc.type article
dc.rights.holder Copyright Associação Brasileira de Divulgação Científica
dc.description.group LIM/03
dc.description.group LIM/09
dc.description.group LIM/14
dc.identifier.doi 10.1590/1414-431x20187138
dc.identifier.pmid 29846436
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author RANGEL, M.P.:FM:
hcfmusp.author ANTONANGELO, L.:FM:MPT
hcfmusp.author ACENCIO, M.M.P.:HC:INCOR
hcfmusp.author FARIA, C.S.:HC:ICHC
hcfmusp.author LONGATTO FILHO, A.:IMT:
hcfmusp.author TAKAGAKI, T.:HC:INCOR
hcfmusp.author CAPELOZZI, V.L.:FM:MPT
hcfmusp.author.external · DE SÁ, V.K.:Universidade de São Paulo, Brazil; AC Camargo Cancer Center, Brasil
· LEÃO, P.S.:Universidade de São Paulo, Brazil
· FARHAT, C.:Universidade de São Paulo, Brazil
· FABRO, A.T.:Universidade de São Paulo, Brazil
· REIS, R.M.:University of Minho, Portugal; Fundação Pio XII, Brasil; PT Government Associate Laboratory, Portugal
hcfmusp.origem.id WOS:000433191700001
hcfmusp.origem.id SCIELO:S0100-879X2018000800603
hcfmusp.origem.id 2-s2.0-85047784880
hcfmusp.relation.reference · Aberle DR, 2013, J CLIN ONCOL, V31, P1002, DOI 10.1200/JCO.2012.43.3110
· Arber S, 1998, NATURE, V393, P805
· FONTANA RS, 1991, CANCER-AM CANCER SOC, V67, P1155, DOI 10.1002/1097-0142(19910215)67:4+<1155::AID-CNCR2820671509>3.0.CO;2-0
· Gadgeel SM, 2016, ADV EXP MED BIOL, V890, P203, DOI 10.1007/978-3-319-24932-2_11
· Hotulainen P, 2005, MOL BIOL CELL, V16, P649, DOI 10.1091/mbc.E04-07-0555
· Howington JA, 2013, CHEST, V143, pE278, DOI 10.1378/chest.12-2359
· Kelloff GJ, 2012, NAT REV DRUG DISCOV, V11, P201, DOI 10.1038/nrd3651
· Ma H, 2013, STAT MED, V32, P3449, DOI 10.1002/sim.5777
· Melamed MR, 2000, CANCER, V89, P2356, DOI 10.1002/1097-0142(20001201)89:11+<2356::AID-CNCR8>3.0.CO;2-Z
· Melo SA, 2015, NATURE, V523, P177, DOI 10.1038/nature14581
· Ono S, 2007, INT REV CYTOL, V258, P1, DOI 10.1016/S0074-7696(07)58001-0
· Rangel M.P., 2015, Braz J Med Biol Res, V48, P557, DOI 10.1590/1414-431X20144300
· TOCKMAN MS, 1986, CHEST, V89, pS324, DOI 10.1378/chest.89.4_Supplement.324S-a
· Wang W, 2006, J CELL BIOL, V173, P395, DOI 10.1083/jcb.200510115
· Wang WG, 2007, NAT REV CANCER, V7, P429, DOI 10.1038/nrc2148
· Wistuba II, 2002, ONCOGENE, V21, P7298, DOI 10.1038/sj.onc.1205806
· Yan B, 2010, ACTA HISTOCHEM, V112, P101, DOI 10.1016/j.acthis.2008.07.007
· [郑育举 Zheng Yuju], 2013, [南方医科大学学报, Journal of Southern Medical University], V33, P1551
· Zhu BB, 2006, CANCER RES, V66, P8640, DOI 10.1158/0008-5472.CAN-06-1443
dc.description.index MEDLINE
dc.identifier.eissn 1678-4510
hcfmusp.citation.scopus 2
hcfmusp.citation.wos 2
hcfmusp.affiliation.country Brasil
hcfmusp.affiliation.country Portugal


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics